Avanços na terapia com células-tronco para doenças neurológicas: Uma revisão abrangente (Novembro-dezembro 2024)

Última atualização: Agosto 17, 2026

Introdução

A terapia com células-tronco emergiu como uma das abordagens mais promissoras no tratamento de diversas doenças neurodegenerativas, incluindo esclerose lateral amiotrófica (SE), Doença de Parkinson (DP), Doença de Alzheimer (ANÚNCIO), e outras doenças que atualmente não têm cura. Ultimamente 2024, avanços significativos foram feitos na aplicação clínica de células-tronco, com numerosos estudos de investigação e ensaios que relatam avanços nos tratamentos com células estaminais para estas condições debilitantes. Este artigo tem como objetivo fornecer uma revisão abrangente dos últimos avanços na terapia com células-tronco para ELA e outras doenças neurológicas., com foco nos progressos alcançados de novembro a dezembro 2024.

Terapia com células-tronco para esclerose lateral amiotrófica (SE)

SE, também conhecida como doença de Lou Gehrig, is a progressive neurodegenerative condition that affects motor neurons in the brain and spinal cord, levando à fraqueza muscular, paralisia, e eventualmente a morte. Current treatments for ALS only address symptom management and do not slow disease progression. No entanto, recent clinical trials have demonstrated the potential of stem cell-based therapies in treating ALS, offering hope for patients and clinicians alike.

Em novembro 2024, a breakthrough study published in The Lancet Neurology highlighted the success of a Phase II clinical trial that utilized mesenchymal stem cells (MSC) derived from adipose tissue in ALS patients. O julgamento, conducted by researchers at the University of California, São Francisco, showed promising results in improving motor function and slowing disease progression in participants. As células-tronco, injected into the cerebrospinal fluid, were observed to reduce inflammation and promote the repair of damaged motor neurons. The results suggested that MSCs could offer neuroprotective effects, potentially delaying the onset of severe symptoms and extending patient survival.

Além disso, a significant development occurred in a collaborative trial between the Mayo Clinic and Harvard Medical School, where induced pluripotent stem cells (iPSCs) derived from ALS patients’ own skin cells were used to generate motor neurons in vitro. O estudo, which reached its first phase of clinical testing in December 2024, demonstrated that the transplant of these patient-specific motor neurons into animal models of ALS led to a marked improvement in neuronal survival and functional recovery. These advancements indicate that iPSC-based therapies hold substantial promise in personalizing ALS treatment, targeting the root cause of the disease with tailored interventions.

Another promising study, which was presented at the Annual Neurodegenerative Diseases Symposium em dezembro 2024, reported the use of neural stem cells (NSC) for ALS treatment. Researchers from the University of Tokyo injected NSCs into the spinal cord of ALS patients. Over a six-month period, the patients showed significant improvements in muscle strength, coordenação, and respiratory function. Although still in its early stages, the study revealed that NSCs could potentially repair and regenerate the motor neurons affected by ALS, making them a crucial element in future ALS therapies.

Doença de Parkinson: Terapias Baseadas em Células-Tronco

Doença de Parkinson (DP) is another neurological disorder for which stem cell therapy has demonstrated notable potential in recent clinical trials. PD is characterized by the degeneration of dopamine-producing neurons in the brain, leading to tremors, rigidez, e bradicinesia. While there is currently no cure for PD, stem cell-based approaches are offering a promising route to alleviate symptoms and even restore lost function.

A landmark trial conducted by the University of Cambridge in the United Kingdom in November 2024 reported the successful transplantation of dopamine-producing neurons derived from human embryonic stem cells (hESCs) into the brains of Parkinson’s patients. The transplanted cells were integrated into the brain’s dopaminergic pathways and began to release dopamine, which improved motor function in patients. O estudo, which has attracted considerable attention in the scientific community, showed that stem cell therapy could not only alleviate symptoms but also address the underlying cause of the disease by replenishing the depleted dopamine levels in the brain.

In a related study published in Medicina da Natureza em dezembro 2024, researchers from Stanford University detailed their efforts to use gene-edited stem cells to treat PD. The study employed CRISPR-Cas9 technology to correct genetic mutations in stem cells before transplanting them into animal models of Parkinson’s. This approach showed promising results, with the corrected stem cells generating healthy dopamine-producing neurons that reversed symptoms of PD in the models. While these findings are still in the preclinical stage, the potential for gene-edited stem cells to offer personalized therapies for Parkinson’s patients is immense.

Doença de Alzheimer: Stem Cells as a Tool for Neuroregeneration

Doença de Alzheimer (ANÚNCIO) is one of the most common and devastating neurodegenerative disorders, characterized by progressive memory loss, declínio cognitivo, e mudanças comportamentais. A incapacidade dos tratamentos existentes de interromper ou retardar a progressão da doença de Alzheimer estimulou a investigação de terapias baseadas em células estaminais que visam regenerar neurónios perdidos e restaurar a função cognitiva..

Em dezembro 2024, um estudo inovador conduzido por pesquisadores da Universidade da Califórnia, Los Angeles (UCLA) mostraram que a terapia com células-tronco poderia potencialmente reverter alguns dos déficits cognitivos associados ao Alzheimer. O estudo envolveu o transplante de células progenitoras neurais (NPCs) derivado de iPSCs em modelos animais de Alzheimer. Os NPCs se integraram ao cérebro e foram capazes de se diferenciar em neurônios, que ajudou a reparar os circuitos neurais danificados. Os animais tratados apresentaram melhorias significativas na memória e na função cognitiva, indicando o potencial de abordagens baseadas em células-tronco para abordar as causas profundas da doença de Alzheimer.

Um ensaio simultâneo no Massachusetts General Hospital, também publicado em dezembro 2024, testaram a aplicação de MSCs em pacientes com Alzheimer leve a moderado. Os resultados iniciais sugeriram que o transplante de MSC poderia melhorar a plasticidade neuronal e melhorar o desempenho cognitivo em pacientes, embora seja necessário um acompanhamento a longo prazo para avaliar a durabilidade destes efeitos. Este ensaio representa um avanço significativo no uso potencial de células-tronco para tratar a doença de Alzheimer e outras formas de demência.

Esclerose múltipla (EM): Células-tronco como uma opção promissora

Esclerose múltipla (EM) é uma doença autoimune que faz com que o sistema imunológico do corpo ataque a bainha de mielina que envolve as fibras nervosas, leading to neurological impairment. Traditional treatments for MS focus on managing flare-ups and slowing disease progression, but they do not regenerate lost nerve tissue. Stem cell therapy has emerged as a potential solution for remyelination and repair of nerve damage in MS.

A promising study in December 2024, conducted by researchers at the University of Oxford, demonstrated the potential of hematopoietic stem cell transplantation (TCTH) in treating MS patients. HSCT involves the transplantation of stem cells from the patient’s bone marrow, followed by a course of chemotherapy to reset the immune system. No estudo, patients who underwent HSCT showed significant improvements in both motor and cognitive function. This approach is gaining traction as a potential therapy for progressive forms of MS.

Além disso, a groundbreaking trial conducted by the National Institutes of Health (NIH) in the United States explored the use of oligodendrocyte precursor cells (OPCs), derived from human stem cells, for remyelinating damaged nerve fibers in MS patients. The Phase I trial, which began in November 2024, has demonstrated early-stage success, with patients showing increased remyelination and improved neurological function after receiving OPC transplants.

Desafios e direções futuras

Despite the promising results seen in recent stem cell trials for neurological diseases, desafios significativos permanecem. One of the primary concerns is the safety of stem cell-based therapies, particularly the risk of tumor formation and immune rejection. Several clinical trials have faced setbacks due to adverse events, and researchers are working diligently to address these issues through better cell sourcing, edição genética, and immune modulation techniques.

Adicionalmente, while current research shows promise, it is still in the early stages, and large-scale, long-term studies are required to fully assess the efficacy and safety of stem cell-based therapies for ALS, DP, ANÚNCIO, EM, and other neurological diseases. Regulatory hurdles and the high cost of treatment are also barriers that need to be overcome for these therapies to become widely accessible.

Conclusão

Para concluir, the period between November and December 2024 has marked a significant period of progress in the field of stem cell therapy for neurological diseases. Breakthrough studies in ALS, Parkinson, Alzheimer, and multiple sclerosis have shown that stem cells have the potential to address some of the most challenging aspects of these diseases, from neuron regeneration to immune modulation and remyelination. Embora ainda existam muitos desafios a serem superados, o progresso alcançado na terapia com células-tronco é uma prova do potencial transformador desta abordagem no tratamento de doenças neurodegenerativas.

À medida que as tecnologias de células-tronco continuam a evoluir, pacientes com distúrbios neurológicos podem esperar tratamentos mais personalizados, tratamentos eficazes no futuro, aproximando-nos de um mundo onde muitas destas doenças podem já não ser intratáveis.

---